 | Up a level |
Felip, Enriqueta, Ardizzoni, Andrea, Ciuleanu, Tudor, Cobo, Manuel, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Carcereny, Enric, Griffiths, Richard, Paz-Ares, Luis, Duchnowska, Renata, Alonso Garcia, Miriam, Isla, Dolores, Jassem, Jacek 
ORCID: 0000-0002-8875-6747, Appel, Wiebke, Milanowski, Janusz, Van Meerbeeck, Jan P., Wolf, Juergen, Li, Ang, Acevedo, Angelic and Popat, Sanjay ORCID: 0000-0003-2087-4963
(2020).
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
Eur. J. Cancer, 127.
S. 160 - 173.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852
Popat, Sanjay ORCID: 0000-0003-2087-4963, Ardizzoni, Andrea, Ciuleanu, Tudor, Dols, Manuel Cobo, Laktionov, Konstantin, Szilasi, Maria, Califano, Raffaele, Costa, Enric Carcereny, Griffiths, Richard, Paz-Ares, Luis, Szczylik, Cezary, Jaime, Jesus Corral, Isla, Dolores, Jassem, Jacek, Appel, Wiebke, van Meerbeeck, Jan, Wolf, Juergen, Jiang, Joel, Molife, L. Rhoda and Felip, Enriqueta
(2017).
Nivolumab in Patients With Previously TreatedMetastatic Squamous Non-Small Cell Lung Cancer (NSCLC): Results of A European Single-Arm, Phase II Trial (CHECKMATE 171) Including Patients Aged >= 70 Years or With Poor Performance Status.
Asia-Pac. J. Clin. Oncol., 13.
S. 149 - 151.
HOBOKEN:
WILEY.
ISSN 1743-7563